ACT Brief: RBQM Financial Value Quantification, Trial Budget Cost Visibility Gap, and GSK mRNA Flu Vaccine Phase III

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a new video interview, Sylviane de Viron of CluePoints, and Abigail Dirks of Tufts CSDD explained how combining real-world deployment data with eNPV modeling finally made it possible to put a number on the financial value of RBQM. Oncology was chosen as a conservative starting point because it has the largest data set, giving the model the highest confidence that results would be defensible across other therapeutic areas.
• In a new contributed article, Tina Mincher and Shelley Douros examined how static budgeting models and one-size-fits-all fair market value approaches create visibility gaps around inflation and true site costs. Regional frameworks, standardized costing toolkits, and accountability metrics can rebuild trust and replace defensive negotiations with transparency.
• GSK is advancing its mRNA seasonal flu vaccine to Phase III testing, starting in September, based on positive Phase II data showing higher immune response against all flu strains compared with licensed vaccines. The vaccine is designed to target both surface proteins that cause the virus to bind and spread, a dual-target approach growing evidence suggests could improve protection and reduce transmission.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.